Time trends in the epidemiology of newly diagnosed stage IV prostate cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988 - 2003)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5059-5059 ◽  
Author(s):  
M. A. Carducci ◽  
K. Cetin ◽  
R. Markus ◽  
J. P. Fryzek
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Time Trends ◽  
Stage Iv ◽  
The United States ◽  
Seer Program ◽  
Newly Diagnosed ◽  
End Results

scholarly journals Recent Time Trends in the Epidemiology of Stage IV Prostate Cancer in the United States: Analysis of Data From the Surveillance, Epidemiology, and End Results Program*

Urology ◽  
2010 ◽  
Vol 75 (6) ◽  
pp. 1396-1404 ◽  
Author(s):  
Karynsa Cetin ◽  
Jennifer L. Beebe-Dimmer ◽  
Jon P. Fryzek ◽  
Richard Markus ◽  
Michael A. Carducci
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Time Trends ◽  
Stage Iv ◽  
The United States ◽  
Recent Time ◽  
End Results

Quality Control of Data in a Large-Scale Cancer Register Program

1966 ◽  
Vol 05 (02) ◽  
pp. 67-74 ◽  
Author(s):  
W. I. Lourie ◽  
W. Haenszeland
Keyword(s):  
United States ◽  
Quality Control ◽  
Cancer Patients ◽  
Large Scale ◽  
The United States ◽  
Newly Diagnosed ◽  
Related Data ◽  
Cancer Register ◽  
Independent Review ◽  
End Results

Quality control of data collected in the United States by the Cancer End Results Program utilizing punchcards prepared by participating registries in accordance with a Uniform Punchcard Code is discussed. Existing arrangements decentralize responsibility for editing and related data processing to the local registries with centralization of tabulating and statistical services in the End Results Section, National Cancer Institute. The most recent deck of punchcards represented over 600,000 cancer patients; approximately 50,000 newly diagnosed cases are added annually.Mechanical editing and inspection of punchcards and field audits are the principal tools for quality control. Mechanical editing of the punchcards includes testing for blank entries and detection of in-admissable or inconsistent codes. Highly improbable codes are subjected to special scrutiny. Field audits include the drawing of a 1-10 percent random sample of punchcards submitted by a registry; the charts are .then reabstracted and recoded by a NCI staff member and differences between the punchcard and the results of independent review are noted.

scholarly journals Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States

Cancer ◽  
2011 ◽  
Vol 118 (5) ◽  
pp. 1260-1267 ◽  
Author(s):  
Sandip M. Prasad ◽  
Xiangmei Gu ◽  
Stuart R. Lipsitz ◽  
Paul L. Nguyen ◽  
Jim C. Hu
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
The United States ◽  
Radiographic Imaging ◽  
Newly Diagnosed ◽  
Inappropriate Utilization

Diabetes mellitus, race, and the odds of high-grade prostate cancer in men diagnosed with prostate cancer in the United States.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 180-180 ◽  
Author(s):  
T. Mitin ◽  
M. Chen ◽  
B. J. Moran ◽  
D. E. Dosoretz ◽  
M. J. Katin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
United States ◽  
Logistic Regression ◽  
African American ◽  
Risk Factor ◽  
The United States ◽  
High Grade ◽  
Newly Diagnosed ◽  
Independent Association

180 Background: African American (AA) men present more frequently with high-grade prostate cancer (PCa) and are also more likely to have diabetes mellitus (DM). We evaluated whether there is an independent association between DM and the risk of high-grade PCa in men diagnosed with PCa, adjusting for the known predictors of high-grade PCa including AA race. Methods: Between 1991 and 2009 15,377 men newly diagnosed with PCa and treated at 1 of 26 centers, were analyzed in 2 cohorts. Multivariable logistic regression was performed to evaluate whether a diagnosis of DM was associated with the odds of Gleason 7 or 8 to 10 PCa, adjusting for AA race, advancing age, PSA level, and DRE findings. Results: AA men (AOR, 1.87; 95% CI, 1.04-3.37, P=0.04) and non-AA men (AOR, 1.61; 95% CI, 1.34-1.93; P<0.001) with diabetes were more likely to have GS 8 to 10 versus GS 6 or less PCa, compared to non-diabetic men. AA as compared to non-AA race was not significantly associated with the odds of having GS 8 to 10 as compared to 6 or less PCa, both in men with a diagnosis of DM (AOR, 1.47; 95% CI, 0.87-2.50; P=0.15) and without DM (AOR, 1.27; 95% CI, 0.92-1.74, P=0.14). AA race, however (AOR, 1.37; 95% CI, 1.17-1.60, P<0.001), but not DM (AOR 1.09; 95% CI, 0.97-1.22, P=0.16), was associated with GS 7 versus 6 or less PCa. Conclusions: A diagnosis of DM is a risk factor for presenting with Gleason 8 to 10 PCa independent of race. [Table: see text] No significant financial relationships to disclose.

Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States

2003 ◽  
Vol 21 (3) ◽  
pp. 496-505 ◽  
Author(s):  
Patti A. Groome ◽  
Brian O’Sullivan ◽  
Jonathan C. Irish ◽  
Deanna M. Rothwell ◽  
Karleen Schulze ◽  
...  
Keyword(s):  
United States ◽  
Stage Iv ◽  
The United States ◽  
Stage I ◽  
Stage Iii ◽  
Hospital Data ◽  
Cancer Specific Survival ◽  
Supraglottic Cancer ◽  
Stage Iv Disease ◽  
End Results

Purpose: We compared the management and outcome of supraglottic cancer in Ontario, Canada, with that in the Surveillance, Epidemiology, and End Results (SEER) Program areas in the United States. Methods: Electronic, clinical, and hospital data were linked to cancer registry data and supplemented by chart review where necessary. Stage-stratified analyses compared initial treatment and survival in the SEER areas (n = 1,643) with a random sample from Ontario (n = 265). We also compared laryngectomy rates at 3 years in those patients 65 years and older at diagnosis. Results: Radical surgery was more commonly used in SEER, with absolute differences increasing with increasing stage: I/II, 17%; III, 36%; and IV, 45%. The 5-year survival rates were 74% in Ontario and 56% in SEER for stage I/II disease (P = .01), 55.7% in Ontario and 46.8% in SEER for stage III disease (P = .40), and 28.5% in Ontario and 29.1% in SEER for stage IV disease (P = .28). Cancer-specific survival results mirrored the overall survival results with the exception of stage IV disease, for which 34.6% of Ontario patients survived their cancer compared with 38.1% in SEER (P = .10). This stage IV difference was more pronounced when we further controlled for possible cause of death errors by restricting the comparison to patients with a single primary cancer (P = .01). Three-year actuarial laryngectomy rates differed. In stage I/II, these rates were 3% in Ontario compared with 35% in SEER (P < 10−3). In stage III disease, the rates were 30% and 54%, respectively (P = .03), and in stage IV disease they were 33% and 64% (P = .002). Conclusion: There are large differences in the management of supraglottic cancer between the SEER areas of the United States and Ontario. Long-term larynx retention was higher in Ontario, where radiotherapy is widely regarded as the treatment of choice and surgery is reserved for salvage. In stages I to III, survival was similar in the two regions despite the differences in treatment policy. In stage IV, there may be a small survival advantage in the U.S. SEER areas related to the higher use of primary surgery.

Sign in / Sign up

Export Citation Format

Share Document